Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.76
OPK's Cash to Debt is ranked lower than
73% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. OPK: 1.76 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s 10-Year Cash to Debt Range
Min: 0.13  Med: 37.81 Max: No Debt
Current: 1.76
Equity to Asset 0.55
OPK's Equity to Asset is ranked lower than
64% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPK: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s 10-Year Equity to Asset Range
Min: -0.41  Med: 0.67 Max: 0.96
Current: 0.55
-0.41
0.96
F-Score: 5
Z-Score: 3.45
M-Score: -3.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -138.33
OPK's Operating margin (%) is ranked lower than
57% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. OPK: -138.33 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s 10-Year Operating margin (%) Range
Min: -31624.44  Med: -408.51 Max: -39.08
Current: -138.33
-31624.44
-39.08
Net-margin (%) -221.97
OPK's Net-margin (%) is ranked lower than
64% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. OPK: -221.97 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s 10-Year Net-margin (%) Range
Min: -44561.54  Med: -421.97 Max: -4.59
Current: -221.97
-44561.54
-4.59
ROE (%) -30.36
OPK's ROE (%) is ranked higher than
51% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. OPK: -30.36 )
Ranked among companies with meaningful ROE (%) only.
OPK' s 10-Year ROE (%) Range
Min: -3196.93  Med: -45.49 Max: -3.98
Current: -30.36
-3196.93
-3.98
ROA (%) -18.87
OPK's ROA (%) is ranked higher than
57% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. OPK: -18.87 )
Ranked among companies with meaningful ROA (%) only.
OPK' s 10-Year ROA (%) Range
Min: -1352.71  Med: -34.23 Max: -0.83
Current: -18.87
-1352.71
-0.83
ROC (Joel Greenblatt) (%) -1390.03
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. OPK: -1390.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130662.93  Med: -1964.13 Max: -55.31
Current: -1390.03
-130662.93
-55.31
Revenue Growth (3Y)(%) 30.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
83% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OPK: 30.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -12.60 Max: 135.1
Current: 30.1
0
135.1
EBITDA Growth (3Y)(%) 69.40
OPK's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. OPK: 69.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.7  Med: 1.10 Max: 171.4
Current: 69.4
-75.7
171.4
EPS Growth (3Y)(%) 139.10
OPK's EPS Growth (3Y)(%) is ranked higher than
99% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. OPK: 139.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.4  Med: -1.60 Max: 152.4
Current: 139.1
-69.4
152.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

OPK Guru Trades in Q3 2014

Murray Stahl 138,935 sh (+10.33%)
George Soros 235,600 sh (unchged)
Paul Tudor Jones Sold Out
Mario Gabelli 11,000 sh (-26.67%)
» More
Q4 2014

OPK Guru Trades in Q4 2014

George Soros 235,600 sh (unchged)
Mario Gabelli 11,000 sh (unchged)
Murray Stahl 125,752 sh (-9.49%)
» More
Q1 2015

OPK Guru Trades in Q1 2015

Ken Fisher 29,200 sh (New)
Jim Simons 1,253,398 sh (New)
Paul Tudor Jones 38,137 sh (New)
Mario Gabelli 11,000 sh (unchged)
George Soros 235,600 sh (unchged)
Murray Stahl 94,824 sh (-24.59%)
» More
Q2 2015

OPK Guru Trades in Q2 2015

Joel Greenblatt 42,947 sh (New)
Paul Tudor Jones 119,791 sh (+214.11%)
Jim Simons 1,907,498 sh (+52.19%)
Murray Stahl 96,810 sh (+2.09%)
George Soros 235,600 sh (unchged)
Ken Fisher 29,200 sh (unchged)
Mario Gabelli 10,000 sh (-9.09%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
Forward P/E 1111.11
OPK's Forward P/E is ranked lower than
98% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. OPK: 1111.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 5.99
OPK's P/B is ranked lower than
65% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. OPK: 5.99 )
Ranked among companies with meaningful P/B only.
OPK' s 10-Year P/B Range
Min: 3.65  Med: 9.00 Max: 50.6
Current: 5.99
3.65
50.6
P/S 40.63
OPK's P/S is ranked lower than
77% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. OPK: 40.63 )
Ranked among companies with meaningful P/S only.
OPK' s 10-Year P/S Range
Min: 15.25  Med: 36.00 Max: 126.5
Current: 40.63
15.25
126.5
PFCF 31.80
OPK's PFCF is ranked higher than
59% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. OPK: 31.80 )
Ranked among companies with meaningful PFCF only.
OPK' s 10-Year PFCF Range
Min: 31.8  Med: 40.92 Max: 49.65
Current: 31.8
31.8
49.65
POCF 30.88
OPK's POCF is ranked higher than
50% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. OPK: 30.88 )
Ranked among companies with meaningful POCF only.
OPK' s 10-Year POCF Range
Min: 30.88  Med: 39.81 Max: 48.23
Current: 30.88
30.88
48.23
Current Ratio 1.54
OPK's Current Ratio is ranked lower than
80% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. OPK: 1.54 )
Ranked among companies with meaningful Current Ratio only.
OPK' s 10-Year Current Ratio Range
Min: 0.88  Med: 6.17 Max: 415
Current: 1.54
0.88
415
Quick Ratio 1.43
OPK's Quick Ratio is ranked lower than
77% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. OPK: 1.43 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s 10-Year Quick Ratio Range
Min: 0.48  Med: 5.85 Max: 415
Current: 1.43
0.48
415
Days Inventory 138.10
OPK's Days Inventory is ranked lower than
56% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. OPK: 138.10 )
Ranked among companies with meaningful Days Inventory only.
OPK' s 10-Year Days Inventory Range
Min: 131.84  Med: 255.62 Max: 500.07
Current: 138.1
131.84
500.07
Days Sales Outstanding 83.58
OPK's Days Sales Outstanding is ranked lower than
64% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. OPK: 83.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s 10-Year Days Sales Outstanding Range
Min: 38.86  Med: 163.92 Max: 727.85
Current: 83.58
38.86
727.85

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 8.32
OPK's Price/Projected FCF is ranked lower than
70% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OPK: 8.32 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s 10-Year Price/Projected FCF Range
Min: 7.16  Med: 16.90 Max: 236.67
Current: 8.32
7.16
236.67
Price/Median PS Value 1.11
OPK's Price/Median PS Value is ranked lower than
56% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. OPK: 1.11 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s 10-Year Price/Median PS Value Range
Min: 0.31  Med: 1.27 Max: 9.49
Current: 1.11
0.31
9.49
Earnings Yield (Greenblatt) (%) -5.07
OPK's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. OPK: -5.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -5.24  Med: 0.00 Max: 0
Current: -5.07
-5.24
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 406 1,170 1,749
EPS($) -0.22 0.01 0.56
EPS without NRI($) -0.22 0.01 0.56

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Mexico, OPK.Israel,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: Shutterstock, Endurance Specialty Holdings, Opko, Air Products, KapStone Aug 31 2015 
Top Insider Buys of the Week Aug 28 2015 
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings Aug 24 2015 
my portfolio Jul 24 2015 
my portfolio Jul 24 2015 
Weekly CEO Buys Highlight: CLMS, OPK, ROVI, LPG, GAM Jul 13 2015 
Weekly CEO Buys Highlight: GPP, CLMS, ADC, SNR, OPK Jul 06 2015 
mio Jun 09 2015 
mio Jun 09 2015 
mio Jun 09 2015 

More From Other Websites
OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Sep 01 2015
5 Big FDA Decisions Expected in September Aug 29 2015
OPKO Letter to Shareholders Aug 26 2015
OPKO HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Aug 26 2015
OPKO Letter to Shareholders Aug 26 2015
OPKO Health to Be Present at the Barrington Research Fall Investment Conference Aug 25 2015
OPKO Health to Be Present at the Barrington Research Fall Investment Conference Aug 25 2015
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings Aug 24 2015
Innospec Set to Join the S&P SmallCap 600 Aug 20 2015
OPKO HEALTH, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation... Aug 20 2015
OPKO Completes Acquisition of Bio-Reference Laboratories Aug 20 2015
OPKO Completes Acquisition of Bio-Reference Laboratories Aug 20 2015
OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services... Aug 20 2015
OPKO Lab Signs Contracts with Leading Preferred Provider Networks for Laboratory Testing Services... Aug 19 2015
OPKO HEALTH, INC. Financials Aug 13 2015
10-Q for OPKO Health, Inc. Aug 07 2015
QLT, Inc. Earnings Q2*, 2015 Aug 07 2015
Edited Transcript of OPK earnings conference call or presentation 5-Aug-15 8:30pm GMT Aug 05 2015
OPKO Health reports 2Q loss Aug 05 2015
OPKO Health reports 2Q loss Aug 05 2015
OPKO HEALTH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2015
OPKO Announces Second Quarter Operating and Financial Results Aug 05 2015
OPKO HEALTH, INC. Files SEC form 10-Q, Quarterly Report Aug 05 2015
OPKO Announces Second Quarter Operating and Financial Results Aug 05 2015
Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th... Aug 05 2015
Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th... Aug 05 2015
Frost Closes SciVac Deal, A Potential Blockbuster Lineup in Hepatitis Aug 05 2015
OPKO To Announce Second Quarter Operating and Financial Results on August 5, 2015 Jul 30 2015
FDA Accepts OPKO's New Drug Application for Rayaldee™ Jul 28 2015
OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources Jul 10 2015
OPKO Announces Completion of Enrollment in Phase 3 Trial of hGH-CTP in Growth Hormone Deficient... Jul 10 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 05 2015
OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned... Jul 02 2015
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes Jul 01 2015
OPKO 4Kscore® Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer... Jun 26 2015
OPKO to Present New Data at International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress... Jun 09 2015
Bio-Reference Laboratories, Inc. Reports Solid Revenues and Earnings for Q2FY15 Jun 08 2015
OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger Jun 08 2015
OPKO Health to Acquire Bio-Reference Laboratories Jun 04 2015
OPKO Health to Acquire Bio-Reference Laboratories Jun 04 2015
OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting May 18 2015
OPKO Health reports 1Q loss May 11 2015
OPKO Health reports 4Q loss Feb 27 2015
OPKO Health misses 3Q revenue forecasts Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK